AXGN Valuation
AxoGen Inc
$
11.570
- Overview
- Forecast
- Valuation
AXGN Relative Valuation
AXGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AXGN is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for AXGN's competitors is 2.80, providing a benchmark for relative valuation. AxoGen Inc Corp (AXGN) exhibits a P/S ratio of 2.39, which is -14.52% above the industry average. Given its robust revenue growth of 17.36%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
GHLD
Guild Holdings Co
13.160
USD
+0.38%
IIIV
I3 Verticals Inc
25.840
USD
+2.26%
DDL
Dingdong (Cayman) Ltd
2.220
USD
-3.48%
MGPI
MGP Ingredients Inc
32.000
USD
-2.05%
ETWO
E2open Parent Holdings Inc
2.710
USD
+1.88%
ADXN
Addex Therapeutics Ltd
8.020
USD
+0.12%
BFLY
Butterfly Network Inc
2.290
USD
-1.29%
SPLP
Steel Partners Holdings LP
35.000
USD
+2.69%
CDMO
Avid Bioservices Inc
12.490
USD
0.00%
BJRI
BJ's Restaurants Inc
42.090
USD
-1.70%
FAQ
Is AxoGen Inc (AXGN) currently overvalued or undervalued?
AxoGen Inc (AXGN) is now in the Fair zone, suggesting that its current forward PS ratio of 2.39 is considered Fairly compared with the five-year average of 3.28. The fair price of AxoGen Inc (AXGN) is between 10.42 to 21.32 according to relative valuation methord.
What is AxoGen Inc (AXGN) fair value?
How does AXGN's valuation metrics compare to the industry average?
What is the current P/B ratio for AxoGen Inc (AXGN) as of May 20 2025?
What is the current FCF Yield for AxoGen Inc (AXGN) as of May 20 2025?
What is the current Forward P/E ratio for AxoGen Inc (AXGN) as of May 20 2025?